Get to know our clinical trials
Trial of ABBV-383 combined with anticancer guidelines in the treatment of patients with relapsed or refractory multiple myeloma.
EL OBJETIVO DE ESTE ESTUDIO ES AVERIGUAR SI ABBV-383 PUEDE COMBINARSE DE MODO SEGURO CON OTRAS PAUTAS CONTRA EL MIELOMA O CON NIROGACESTAT, DETERMINAR LA DOSIS MÁS SEGURA DE ABBV-383 EN COMBINACIÓN CON LAS OTRAS PAUTAS CONTRA EL MIELOMA O CON NIROGACESTAT Y SI LAS COMBINACIONES PRODUCEN UNA ACTIVIDAD ANTIMIELOMA SIGNIFICATIVA EN PACIENTES CON MIELOMA MÚLTIPLE (MM) RECIDIVANTE O RESISTENTE
Technical Summary
- ESTUDIO DE AUMENTO ESCALONADO Y AMPLIACIÓN DE LA DOSIS DE ABBV- 383 COMBINADO CON PAUTAS CONTRA EL CÁNCER EN EL TRATAMIENTO DE PACIENTES CON MIELOMA MÚLTIPLE RECIDIVANTE O RESISTENTE.
- Code EudraCT: 2021-005587-22
- Protocol number: M22-947
- Promoter: Abbvie farmacéutica
* The trials only admit a limited number of patients and are subject to inclusion and exclusion criteria. The specialist who assesses your case will inform you of the conditions required to participate in the clinical trial.
More information about this clinical trial
Information offered by the Spanish Registry of Clinical Studies
- Summary
- Information
- Calendar
- Headquarters
- Drugs
Do you want to participate in this trial?
Request an appointment for our specialists to assess whether you qualify for this clinical trial
Do you prefer to send us your reports?
If you prefer, you can send us your medical information and our specialists will evaluate your case without the need to come to the Clinica.